Literature DB >> 21279982

Intravitreal bevacizumab to treat choroidal neovascularization following photodynamic therapy in central serous choroidopathy.

Javier A Montero1, José M Ruiz-Moreno, Marta Fernandez-Muñoz.   

Abstract

PURPOSE: To report the anatomic and functional outcome of intravitreal bevacizumab (IVB) to treat choroidal neovascularization (CNV) following photodynamic therapy (PDT) to treat recurrent central serous choroidopathy (CSC).
METHODS: This was an interventional case report in which verteporfin PDT was performed in a case of recurrent CSC.
RESULTS: Following PDT, the patient developed juxtafoveal CNV that was later treated by IVB, achieving CNV closure and recovery of visual acuity.
CONCLUSIONS: Photodynamic therapy is a useful therapy to treat recurrent CSC, though it may be associated with potentially severe complications such as CNV. Intravitreal bevacizumab seems a good alternative treatment in the management of this condition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21279982     DOI: 10.5301/EJO.2011.6290

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  5 in total

Review 1.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

2.  Risk Factors and Outcomes of Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy.

Authors:  Ga-In Lee; A Young Kim; Se Woong Kang; Soo Chang Cho; Kyu Hyung Park; Sang Jin Kim; Kyung Tae Kim
Journal:  Sci Rep       Date:  2019-03-08       Impact factor: 4.379

3.  Short-term effect of anti-VEGF for chronic central serous chorioretinopathy according to the presence of choroidal neovascularization using optical coherence tomography angiography.

Authors:  Yong-Yeon Song; Hwa-Young Yu; Seung-Kook Baek; Young-Hoon Lee; Min-Woo Lee
Journal:  PLoS One       Date:  2021-01-11       Impact factor: 3.240

Review 4.  Advances in the treatment of central serous chorioretinopathy.

Authors:  Marwan A Abouammoh
Journal:  Saudi J Ophthalmol       Date:  2015-01-24

Review 5.  Management of chronic central serous chorioretinopathy.

Authors:  Daren Hanumunthadu; Anna C S Tan; Sumit Randhir Singh; Niroj Kumar Sahu; Jay Chhablani
Journal:  Indian J Ophthalmol       Date:  2018-12       Impact factor: 1.848

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.